蓝帆医疗: 第六届董事会第二十四次会议决议公告

Group 1 - The company held its 24th meeting of the 6th Board of Directors on June 19, 2025, via electronic communication, with all 8 directors participating [1] - The meeting confirmed that the company's stock had closed below 85% of the current conversion price for at least 15 out of the last 30 trading days, triggering the condition for downward adjustment of the "Lanfan Convertible Bonds" conversion price [1][2] - The Board proposed to adjust the conversion price of the "Lanfan Convertible Bonds" downward, which requires approval from the shareholders' meeting [2] Group 2 - The adjusted conversion price will not be lower than the higher of the average trading price over the 20 trading days prior to the shareholders' meeting and the trading price on the last trading day, and it must also not be lower than the latest audited net asset value per share and the par value of the stock [2] - If any of the aforementioned indicators exceed the current conversion price of 12.50 yuan per share at the time of the shareholders' meeting, no adjustment will be made [2] - The Board requested authorization from the shareholders' meeting to handle all matters related to the downward adjustment of the conversion price, including determining the new conversion price and effective date [2][3]